Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
APPY agreed Bob maybe best risk/reward bio right now been basing for 4 weeks here & trading at Cash. Also analyst target at $7.00 share with near term catalysts
http://seekingalpha.com/article/1486211-canaccord-genuity-sees-strong-upside-in-venaxis-shares-and-set-a-7-price-target?source=yahoo
APPY 25 Mill $$ Mkt Cap with 23 mill in Cash & paltry 2 mill a Qtr cash burn 20 mill shares outstanding & entering a potential 200 to 700 mill $$$ market for the ONLY appendicitis test on the market. Oversold & ready for nice move back up over $1.50 strong 3rd Qtr catalyst on trial results which 1st one at 97%.Imo only APPY is a very strong Risk/Reward setup here where offering was just completed.
Analyst target $7.00 a share Link
http://seekingalpha.com/article/1486211-canaccord-genuity-sees-strong-upside-in-venaxis-shares-and-set-a-7-price-target?source=yahoo
APPY agreed maybe best risk/reward play out there right now see little to no downside & clearly double digit % gains if not triple for the patient investor waiting for trial news later this year GLTA & make $$$$$$$$$$$$$$
APPY 25 Mill $$ Mkt Cap with 23 mill in Cash & paltry 2 mill a Qtr cash burn 20 mill shares outstanding & entering a potential 200 to 700 mill $$$ market for the ONLY appendicitis test on the market. Oversold & ready for nice move back up over $1.50 strong 3rd Qtr catalyst on trial results which 1st one at 97%.Imo only APPY is a very strong Risk/Reward setup here where offering was just completed.
Analyst target $7.00 a share Link
http://seekingalpha.com/article/1486211-canaccord-genuity-sees-strong-upside-in-venaxis-shares-and-set-a-7-price-target?source=yahoo
APPY thanks Sheff found in board intro long APPY s/b be bottomed as oversold & near term catalysts kick in.
APPY Sheff are you currently in APPY thanks as looks bottomed & now plenty of cash to get through FDA. Plus we may see some revenues from European approval
Levy didn't come aboard for a paycheck guy is filthy rich... He see's a high growth opportunity & imo was brought in to close big deals ....thinking Casino deals....Waiting for compensation 8K as I'll bet heavy incentives in his deal...Either way between Fanthrowdown, Hammercat studios & new gambling game apps & patent case MGT at 28 million dollar market cap & 9 Million in Cash with No Debt is looking very cheap imo..... GLTA & make $$$$$$$$$$$$$$$$$$$$$$$$$$$
Levy is a big time haul for tiny MGT Tier 1 connections & some resume...
http://en.wikipedia.org/wiki/Mike_Levy
Line I love the most Partnerships & this guy will land them think Casino deals
I look forward to working closely with management to formulate strong marketing and sales plans, and also to help structure meaningful strategic partnerships."
MGT news hires Mike Levy true tier 1 player with big time resume
http://en.wikipedia.org/wiki/Mike_Levy
http://finance.yahoo.com/news/mgt-capital-investments-inc-retains-131500470.html
TGTX great find & Uplisting to Nasdaq tomorrow morning same symbol
MGT Vol break Fri legal online gambling/patent play with tiny 3 mill share float getting lots of exposure & increased volume gonna blow up back to 52 week hi's of mid $7's imo as news flow about to start this week
PSDV PDUFA later this year & should have popped with ALIM in also
MGT thanks for link here are a couple to S/A pieces must be 7 or 8 different authors on MGT lots of new eyes picking up on MGT hence the volume change starting in early April at $3.00 a share
http://seekingalpha.com/article/1412991-key-meetings-likely-to-bring-wms-and-mgt-closer-to-settlement
http://seekingalpha.com/article/1386071-near-term-catalyst-provides-attractive-opportunity-for-mgt-capital-investors
http://seekingalpha.com/article/1373691-mgt-capital-diversifies-operations-by-entering-a-high-growth-business
And lastly a link to all articles as way to many & picking up steam on breakout
http://seekingalpha.com/symbol/mgt
I can see why many retail investors bailed today as at first glance didn't seem like good news but after spending nearly 30 minutes on the phone with CEO this is good news & here's why.
The scummy financiers which could give a crap about ANY co. they are involved in started exercising warrants note that only 2.4 of the 2.7 million warrants are involved ??? Hudson & Iroqouis already exercised 300K flipped in $4s'. Management saw this & acted quickly as they don't want several months of overhang & constant selling like they did with the preferred shares. This gives them 800K free trading if exercised in full & 1 million shares restricted for 6 months & eliminates 600K warrants reducing total outstanding shares. My feeling is they have good news coming & want these lowlifes out of the way so investors get into a free trading stock. Remember the largest shareholder is the CEO & CFO owning 27% of the total out. Next few weeks & months I see lots of good news coming & this clears the way for the stock to trade at much higher valuations.CEO wants Institutional sponsorship & needs the share price much higher to garner their interest & remember CEO a 25 year hedge fund experienced veteran knows the system believe me he is sharp. Just my opinion but I believe this stock has maybe another week or 2 at these levels & then will be at much higher prices... GLTA & make $$$$$$$$$$$$$$$$$$$$$$
MGT recent runner pulling back to support area got some back $3.60's
http://www.forbes.com/sites/richardfinger/2013/04/14/mgt-capital-will-it-make-millions-from-casino-lawsuits/?partner=yahootix
ATHX thanks posted MGT DD also been a beast put in here $3.20 now $4.37 great potential on patent play. Keep an eye for pullback
http://www.forbes.com/sites/richardfinger/2013/04/14/mgt-capital-will-it-make-millions-from-casino-lawsuits/?partner=yahootix
ATHX yeah I foolishly let it go mid $1.80's on a $1.61 avg cost wanted it back cheaper but never got a re entry ughhhhh GLTA & make $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
MGT Forbes article out great read & potential link
http://www.forbes.com/sites/richardfinger/2013/04/14/mgt-capital-will-it-make-millions-from-casino-lawsuits/?partner=yahootix
MGT your welcome Bob & considering the historic Vol twice in last few days I expect a trip back To $6's or $7's soon as multiple catalysts coming for MGT....
O.T. MGT not a biotech play but gotta share some DD on a dirt cheap potential monster...
MGT has over 5 million in cash & a 11 million dollar market cap. Their angle is their gaming patent which is quite simple to understand filed in 2001 issued finally in 2011 & MGT suing CZR MGM PENN WMS & azure.
CEO is a v fund manager that invested in MGT likes the case & became CEO plus put down over 2 million out his pocket into MGT stock owns over 25%.
MGT patent attorney a top tier 1 law firm highly praised & took MGT case on a contingency basis which speaks volumes about this case.
Plenty of links starting with co. presentation note the potential value compared to current market cap also links to multiple seeking alpha authors
http://files.shareholder.com/downloads/MSHT/2410771022x0x611222/54081cc0-27b3-4ec3-b5d7-680ec0823c0d/Nov%202012%20preso.pdf
http://seekingalpha.com/article/1319801-key-patent-players-stocks-with-large-potential?source=yahoo
http://seekingalpha.com/article/1311641-an-analysis-of-mgt-s-patent-and-its-legal-counsel?source=yahoo
http://seekingalpha.com/article/1303421-stocks-with-upcoming-legal-catalysts?source=yahoo
http://seekingalpha.com/article/1238281-mgt-capital-small-patent-stock-with-huge-potential?source=yahoo
ATHX anyone else looking at this co. S/A article interesting pipeline link
http://seekingalpha.com/article/1305311-athersys-inc-has-blockbuster-potential?source=yahoo
congrats Sheff what a Qtr.... I had 1 of my best Qtr's as well with TTNP the biggest $$$ winner by far for me. What was your top 3 winners in that 394K 1st Qtr ??? BTW looking forward to great last 3 Qtr's with Sheff & crew GLTA & make $$$$$$$$$$$$$$$$$$$$$$$$
ATHX great Vol & price action again today.
MSTX newswire. Mast Therapeutics Engages ESC Advisors To Identify Partnering Opportunities For MST-188
SAN DIEGO, March 28, 2013 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that it has engaged ESC Advisors, a division of the investment banking firm KEMA Partners LLC, to serve as its exclusive financial advisor to identify potential partners for MST-188 and advise the Company in transaction discussions.
Brian M. Culley, Chief Executive Officer, said: "Given the high unmet need and limited treatment options, sickle cell disease is experiencing significant levels of interest from strategic partners. MST-188 is now the only new molecular entity in phase 3 development in sickle cell disease. Based on its stage of development, the absence of competitive, novel and late-stage products, its designation as an orphan drug in the U.S. and Europe and its potential utility in additional indications, we believe there will be substantial interest in MST-188 from potential partners, both in the U.S. and globally, and we intend to pursue strategic alliances aggressively. ESC's experience in transactions involving orphan product candidates will complement our internal capabilities and expand the scope of our current and future partnering discussions."
About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, CA. The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, its lead product candidate, for serious or life-threatening diseases with significant unmet needs. MST-188 is a cytoprotective, hemorheologic, anti-inflammatory and antithrombotic agent that has potential utility in diseases or conditions characterized by microcirculatory insufficiency (endothelial dysfunction and/or impaired blood flow).
The Company is recruiting subjects in EPIC, a pivotal phase 3 study of MST-188 in sickle cell disease. The Company plans to initiate a phase 2 clinical study of MST-188 in acute limb ischemia, a complication of peripheral arterial disease, in late 2013 or early 2014. More information can be found on the Company's web site at www.masttherapeutics.com.
ONCY good news out also gapper
RPRX 14 million share float 5.3 Million shares Short lots of wake up pain for shorties.
MSTX hmm late stage phase 3 drug trading below cash on hand
As of December 31, 2012, the Company had cash, cash equivalents and short-term investments totaling $36.5 million. Stockholders' equity amounted to $41.8 million as of December 31, 2012. The Company's contingent asset related to the consideration for the acquisition of SynthRx in April 2011 was settled in December 2012. The Company recorded the fair value of the contingent asset as of the settlement date as an adjustment to equity and recognized as a transaction-related expense the increase in its fair value as of its settlement date relative to December 31, 2011 Re: Orphan status granted plus trading for less then CASH on hand Re: European ...
TTNP nice vol this a.m. when pre meeting doc's out could really start moving back to 52 week Hi's GLTA & make $$$$$$$$$$$$$$$
Just out on Briefing Titan Pharma initiated with a Market Perform at Brinson Patrick; tgt $5 (2.04 +0.17)
Brinson Patrick initiates TTNP with a Market Perform and price target of $5. They believe many of the chronic patients will switch to Probuphine, but their models only assume a single-digit share. They believe the FDA has every reason under the sun to approve Probuphine. Probuphine's clinical package is impressive, they have no doubt Probuphine effectively reduces an addicts drug abuse habits...based on the results of Probuphine's Phase 3 trials. An FDA Advisory Committee will release their briefing documents March 19th that will give investors insights into the FDA's April 30th PDUFA decision. They believe the Advisory Committee will be a platform for drug abuse experts to pound the table for this treatment and they encourage investors to buy TTNP shares ahead of that event.
TTNP just out on Briefing.. Titan Pharma initiated with a Market Perform at Brinson Patrick; tgt $5 (2.04 +0.17)
Brinson Patrick initiates TTNP with a Market Perform and price target of $5. They believe many of the chronic patients will switch to Probuphine, but their models only assume a single-digit share. They believe the FDA has every reason under the sun to approve Probuphine. Probuphine's clinical package is impressive, they have no doubt Probuphine effectively reduces an addicts drug abuse habits...based on the results of Probuphine's Phase 3 trials. An FDA Advisory Committee will release their briefing documents March 19th that will give investors insights into the FDA's April 30th PDUFA decision. They believe the Advisory Committee will be a platform for drug abuse experts to pound the table for this treatment and they encourage investors to buy TTNP shares ahead of that event.
TTNP also seeking alpha piece out link
http://seekingalpha.com/article/1276251-titan-presents-compelling-opportunity-ahead-of-pdac-vote?source=yahoo
TTNP Street A Feuerstein out with video on TTNP nice getting bigger attention....
http://www.thestreet.com/_yahoo/video/11869889/the-next-big-thing-in-biotech-titan.html?cm_ven=YAHOOV&cm_cat=FREE&cm_ite=NA&s=1
TTNP nice reminder Sheff also Analyst Jason Napodano thoughts on clinical data of TTNP
http://bionapcfa.blogspot.com/search/label/Titan%20Pharma
Titan completed two phase III trials and two long-term safety analyses with Probuphine. Data from the first phase III trial was published in JAMA (2010; 304(14):1576-1583) in October 2010. Various posters of the data have been presented at the American College of Neuropsychopharmacology in December 2009 (ACNP Poster-1), the International Society of Addiction Medicine in September 2011 (ISAM Poster-2), and the American Society of Addiction Medicine in April 2012 (ASAM Poster-3).
We view the data as impressive. Probuphine works, and the concept is ideally suited for curbing addictive behavior without risk of accidental exposure or misuse / abuse. We're bullish on the prospects for the drug. We base our opinion on the strong clinical data, the thoughtful and rational design for the product, and various conversations we've had with management and lead investigators from the confirmatory phase III trial. In August 2011, Titan hosted a call with Dr. Walter Ling, M.D., Professor of Psychiatry and Director, Integrated Substance Abuse Programs at the David Geffen School of Medicine at UCLA and Dr. Richard N. Rosenthal, M.D., Chairman of Psychiatry at St. Luke's-Roosevelt Hospital Center, a teaching hospital of Columbia University, past president of the American Academy of Addiction Psychiatry. Both doctors expressed their enthusiasm for Probuphine and why they believe it will see meaningful commercial uptake.
As noted above, in the U.S. there are an estimated 3.7 million individuals addicted to opioids. Currently, Suboxone does around 500,000 prescriptions monthly. We model that Probuphine can capture 20% of these patients at a cost of around $2,000 per course of treatment, with an estimated 40% of patients requiring two implants. Therefore, in the U.S. alone, Probuphine is a $280 million product.
TTNP short interest #'s out this A.M. big drop went from 1,461,000 to 1,060,000 last 2 weeks & expect it lower again next report as I sure wouldn't want to be short into positive adcom....
TTNP Kei this would have already re visited 52 week Hi's $2.50 area if not for warrant selling & accumulated by big boys very orderly the last few weeks ...a very positive sign
TTNP perhaps warrant seller done $1.82 s/b much higher into next weeks adcom.
TTNP spoke to CEO & he was shocked this data was an issue as from 2008 & 3 phase 3 trials done after & all data positive & will have NO bearing on Adcom or PDUFA = big buying opp in my opinion GLTA & make $$$$$$$$$$
TTNP correct & director 112K dollars laid out by the 2 of them out of their pocket...
Wow what a gift that would be... love to reload at $1.10 barring any really bad news never will happen...